These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33228575)

  • 1. Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms?
    Jen YW; Hwang TJ; Chan HY; Hsieh MH; Liu CC; Liu CM; Hwu HG; Kuo CH; Lin YT; Chien YL; Chen WJ
    BMC Psychiatry; 2020 Nov; 20(1):552. PubMed ID: 33228575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
    Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
    Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics.
    Hwang TJ; Lo WM; Chan HY; Lin CF; Hsieh MH; Liu CC; Liu CM; Hwu HG; Kuo CH; Chen WJ
    J Clin Psychopharmacol; 2015 Dec; 35(6):635-44. PubMed ID: 26488675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study.
    Yoon HW; Lee JS; Park SJ; Lee SK; Choi WJ; Kim TY; Hong CH; Seok JH; Park IH; Son SJ; Roh D; Kim BR; Lee BO
    Clin Neuropharmacol; 2016; 39(6):288-294. PubMed ID: 27438182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study.
    Lodhi RJ; Masand S; Malik A; Shivakumar K; McAllister VD; O'Keane V; Young LC; Heald AH; Sherwood RA; Aitchison KJ
    Schizophr Res; 2016 Feb; 170(2-3):245-51. PubMed ID: 26792297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series.
    Naono-Nagatomo K; Naono H; Abe H; Takeda R; Funahashi H; Uchimura D; Ishida Y
    Asian J Psychiatr; 2017 Feb; 25():36-41. PubMed ID: 28262171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis.
    Labad J; Montalvo I; González-Rodríguez A; García-Rizo C; Crespo-Facorro B; Monreal JA; Palao D
    Schizophr Res; 2020 Aug; 222():88-96. PubMed ID: 32507371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole-Induced Hypoprolactinemia in an Adult Male with First-Episode Psychosis.
    Propst AJ; Jarvis GE; Margolese HC
    Clin Schizophr Relat Psychoses; 2016; 9(4):173-6. PubMed ID: 25711510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
    Correll CU; Kohegyi E; Zhao C; Baker RA; McQuade R; Salzman PM; Sanchez R; Nyilas M; Carson W
    J Am Acad Child Adolesc Psychiatry; 2017 Sep; 56(9):784-792. PubMed ID: 28838583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil.
    Kelly DL; Claxton A; Bidollari I; Du Y
    Psychiatry Res; 2021 Aug; 302():114030. PubMed ID: 34118485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
    Kim CY; Chung S; Lee JN; Kwon JS; Kim DH; Kim CE; Jeong B; Jeon YW; Lee MS; Jun TY; Jung HY
    Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial.
    Zhao J; Song X; Ai X; Gu X; Huang G; Li X; Pang L; Ding M; Ding S; Lv L
    PLoS One; 2015; 10(10):e0139717. PubMed ID: 26448615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia A Retrospective Case Series.
    Yeager A; Shad MU
    Prim Care Companion CNS Disord; 2020 Jan; 22(1):. PubMed ID: 31999895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report.
    Yang HJ; Kim SG; Seo EH; Yoon HJ
    BMC Psychiatry; 2022 Jan; 22(1):74. PubMed ID: 35093063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
    Weiden PJ; Du Y; Liu CC; Stanford AD
    CNS Spectr; 2019 Aug; 24(4):419-425. PubMed ID: 29941057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature.
    Kuloglu M; Ekinci O; Albayrak Y; Caykoylu A
    Arch Womens Ment Health; 2010 Oct; 13(5):443-7. PubMed ID: 20179976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.